Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-ALK7

Next Previous
Search
Trial Profile

Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-ALK7

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARO ALK7 (Primary) ; Tirzepatide
  • Indications Metabolic disorders; Obesity
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 06 Mar 2025 According to an Arrowhead Pharmaceuticals media release, company anticipates initial data from the single-ascending dose portion of the study possible by year end 2025.
    • 25 Feb 2025 According to an Arrowhead Pharmaceuticals media release, company anticipates will begin dosing in the second quarter of 2025.
    • 10 Feb 2025 According to Arrowhead Pharmaceuticals media release, company received regulatory clearance in New Zealand to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNAi therapeutic being developed as a potential treatment for obesity.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top